Post Doctoral Position in Drug Delivery
Sort on published: 2017-11-21
Uppsala University is a comprehensive research-intensive university with a strong international standing. Our mission is to pursue top-quality research and education and to interact constructively with society. Our most important assets are all the individuals whose curiosity and dedication make Uppsala University one of Sweden’s most exciting workplaces. Uppsala University has 40,000 students, 7,000 employees and a turnover of SEK 6.5 billion.
3D-printed personalized medications for children suffering from severe diseases
The Department of Pharmacy offers a stimulating multidisciplinary working environment in research and teaching within the Pharmacy disciplines. The Department centers its research on Drug Delivery, Rational Drug Usage and Pharmaceutical Materials Science. The research is developed by a series of research groups, several of international prominence. The research groups represent a unique cluster of academic competences in Sweden and the Department of Pharmacy has thus a key role in the development of the pharmacy discipline in Sweden. Information about the department and the research groups can be found at www.farmfak.uu.se/farm/.
The post doc will be linked to the research group Drug Delivery. The group takes a multidisciplinary approach and combines computational chemistry and bioinformatics with cell- and molecular biology, biopharmaceutics, pharmaceutics and physical chemistry to find new ways to predict and define rate-limiting barriers to the absorption and organ distribution of different types of drugs. We anticipate that our research will provide insights into new mechanisms for drug absorption, disposition and delivery, which will support development of new therapeutic strategies for efficient oral drug delivery.
The post doc will work within the project Personalized medications for children suffering from severe diseases. In this project a clinical platform for development and manufacturing of personalized medications will be developed to provide improved, safer and more convenient drug therapies for children suffering from cancer or neurological diseases. Common for these diseases is that many of the current therapies are not designed for children. The need to develop pediatric dosage forms is enormous and of high importance to safer, efficient and convenient treatment; personalized medications can significantly contribute to improved therapies. In Uppsala unique concepts around drug delivery and advanced drug carriers have been developed. We have discovered the mesoporous material Upsalite and established new concepts around lipid-based drug delivery systems. These two different materials enable dosage forms to be tailored to produce the needed therapeutic concentration of the drug. In this project and multidisciplinary approach is taken to establish a clinical platform based on these different formulation strategies and small scale automated additive manufacturing, with the purpose to develop and produce personalized medication suitable for children. The post doc will work with these new drug carriers and study their potential to be used in advance additive extemporaneous manufacturing through e.g. 3D printing of tablets or films. Further, these materials will be investigated for their use in automated dispensers of these powder and solutions in capsules. Drug release will be studied in vitro for which biorelevant in vitro models will be developed. The project will be finalized with studies in vivo. Techniques to be used in the project are strongly related to pharmaceutics with material and particle characterization, dissolution and release studies, and concentration determination with HLC-UV-MS/MS.
Qualifications: A PhD degree in a subject that is relevant for the project must have been acquired no more than three years prior to the application deadline (prolonged periods of parental leave, illness, military service, union duties or similar may be deducted). Extra attention will be paid to scientific skills and e.g. PhD in Pharmaceutics, Chemical Engineering or other relevant area is highly rated. Previous work with 3D printing techniques is meritorious. The candidate must have good communication skills in oral and written English. Further the post doc is expected to successfully perform high quality research, publish the results, develop new methodologies and independently perform the tasks included in the project. He/she is also expected to actively contribute to other projects performed in the group.
How to apply: The application should contain a letter in which the applicant describes her- or himself, motivates why she/he has applied for the position, states relevant qualifications and indicates research interests and plans for the future. It must contain a CV including at least two references, authorized copies of relevant certificates, degrees and grades, and copies of your master thesis and other documents, such as publications, that you want to invoke.
Salary: According to local agreement
Starting date: 2018-01-15 or otherwise agreed
Type of position: Temporary full-time position, 2 years
For further information about the position please contact Associate Professor Christel Bergström, tel 018-471 4118, e-post firstname.lastname@example.org.
Please submit your application by 07-12-2017, UFV-PA 2017/4079.
Are you considering moving to Sweden to work at Uppsala University? If so, you will find a lot of information about working and living in Sweden at www.uu.se/joinus. You are also welcome to contact International Faculty and Staff Services at email@example.com.
We decline offers of recruitment and advertising help. We only accept the application the way described in the advertisement.
Placement: Department of Pharmacy
Type of employment: Full time , Temporary position longer than 6 months
Pay: Fixed salary
Number of positions: 1
Working hours: 100%
County: Uppsala län
Ellena Papaioannou, Seko
Per Sundman, Saco-rådet 018-471 1485
Suzanne Borén Andersson, TCO/ST 018-471 6251
Number of reference: UFV-PA 2017/4079
Last application date: 2017-12-07